Cargando…

Role of pseudohypoxia in the pathogenesis of type 2 diabetes

Type 2 diabetes is caused by persistent high blood glucose, which is known as diabetic hyperglycemia. This hyperglycemic situation, when not controlled, can overproduce NADH and lower nicotinamide adenine dinucleotide (NAD), thereby creating NADH/NAD redox imbalance and leading to cellular pseudohyp...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Jing, Yang, Xiaojuan, Yan, Liang-Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6560198/
https://www.ncbi.nlm.nih.gov/pubmed/31240235
http://dx.doi.org/10.2147/HP.S202775
_version_ 1783425922507997184
author Song, Jing
Yang, Xiaojuan
Yan, Liang-Jun
author_facet Song, Jing
Yang, Xiaojuan
Yan, Liang-Jun
author_sort Song, Jing
collection PubMed
description Type 2 diabetes is caused by persistent high blood glucose, which is known as diabetic hyperglycemia. This hyperglycemic situation, when not controlled, can overproduce NADH and lower nicotinamide adenine dinucleotide (NAD), thereby creating NADH/NAD redox imbalance and leading to cellular pseudohypoxia. In this review, we discussed two major enzymatic systems that are activated by diabetic hyperglycemia and are involved in creation of this pseudohypoxic condition. One system is aldose reductase in the polyol pathway, and the other is poly (ADP ribose) polymerase. While aldose reductase drives overproduction of NADH, PARP could in contrast deplete NAD. Therefore, activation of the two pathways underlies the major mechanisms of NADH/NAD redox imbalance and diabetic pseudohypoxia. Consequently, reductive stress occurs, followed by oxidative stress and eventual cell death and tissue dysfunction. Additionally, fructose formed in the polyol pathway can also cause metabolic syndrome such as hypertension and nonalcoholic fatty liver disease. Moreover, pseudohypoxia can also lower sirtuin protein contents and induce protein acetylation which can impair protein function. Finally, we discussed the possibility of using nicotinamide riboside, an NAD precursor, as a promising therapeutic agent for restoring NADH/NAD redox balance and for preventing the occurrence of diabetic pseudohypoxia.
format Online
Article
Text
id pubmed-6560198
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-65601982019-06-25 Role of pseudohypoxia in the pathogenesis of type 2 diabetes Song, Jing Yang, Xiaojuan Yan, Liang-Jun Hypoxia (Auckl) Review Type 2 diabetes is caused by persistent high blood glucose, which is known as diabetic hyperglycemia. This hyperglycemic situation, when not controlled, can overproduce NADH and lower nicotinamide adenine dinucleotide (NAD), thereby creating NADH/NAD redox imbalance and leading to cellular pseudohypoxia. In this review, we discussed two major enzymatic systems that are activated by diabetic hyperglycemia and are involved in creation of this pseudohypoxic condition. One system is aldose reductase in the polyol pathway, and the other is poly (ADP ribose) polymerase. While aldose reductase drives overproduction of NADH, PARP could in contrast deplete NAD. Therefore, activation of the two pathways underlies the major mechanisms of NADH/NAD redox imbalance and diabetic pseudohypoxia. Consequently, reductive stress occurs, followed by oxidative stress and eventual cell death and tissue dysfunction. Additionally, fructose formed in the polyol pathway can also cause metabolic syndrome such as hypertension and nonalcoholic fatty liver disease. Moreover, pseudohypoxia can also lower sirtuin protein contents and induce protein acetylation which can impair protein function. Finally, we discussed the possibility of using nicotinamide riboside, an NAD precursor, as a promising therapeutic agent for restoring NADH/NAD redox balance and for preventing the occurrence of diabetic pseudohypoxia. Dove 2019-06-05 /pmc/articles/PMC6560198/ /pubmed/31240235 http://dx.doi.org/10.2147/HP.S202775 Text en © 2019 Song et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Song, Jing
Yang, Xiaojuan
Yan, Liang-Jun
Role of pseudohypoxia in the pathogenesis of type 2 diabetes
title Role of pseudohypoxia in the pathogenesis of type 2 diabetes
title_full Role of pseudohypoxia in the pathogenesis of type 2 diabetes
title_fullStr Role of pseudohypoxia in the pathogenesis of type 2 diabetes
title_full_unstemmed Role of pseudohypoxia in the pathogenesis of type 2 diabetes
title_short Role of pseudohypoxia in the pathogenesis of type 2 diabetes
title_sort role of pseudohypoxia in the pathogenesis of type 2 diabetes
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6560198/
https://www.ncbi.nlm.nih.gov/pubmed/31240235
http://dx.doi.org/10.2147/HP.S202775
work_keys_str_mv AT songjing roleofpseudohypoxiainthepathogenesisoftype2diabetes
AT yangxiaojuan roleofpseudohypoxiainthepathogenesisoftype2diabetes
AT yanliangjun roleofpseudohypoxiainthepathogenesisoftype2diabetes